A new invoice aims to facilitate the restrictions for cannabis and other drug research in Schedule I

The representatives Dina Titus and Ilhan Omar have introduced the Evidence -based drug policy law of 2025 (EBDPA) and tried to remove federal barriers for the examination of substances I., including cannabis, MDMA and psilocybin. The draft law suggests the cancellation of sections of the law on the Reauthorization Act of Office of National Drug Controllization of 1998, which prohibits federal funds on supporting research on these substances and specifying opposition to their legalization.

Treat research restrictions

Currently, the classification of Schedule I describes substances without “non -accepted medical use” and a “high potential for abuse” and limited scientific studies. Nevertheless, many states have legalized medical cannabis and emphasized an interruption between the practices of the federal government and at the state level. The EBDPA aims to focus on the federal research skills on the developing legal landscape and health needs.

Potential effects on drug policy

By facilitating research, the EBDPA could inform EbdPa evidence -based laws and contribute to the evaluation of medication on cannabis. It also opens up paths for the examination of the therapeutic potential of other substances for schedule -i substances. While the legislation has received support for his scientific approach, his passage in the current political climate remains uncertain.